 |
1 Disease |  |
67 Trials |
|
67 Trials |  |
1555 News |  |
| «12345678910111213...3940» |
- | Libtayo (cemiplimab-rwlc) / Regeneron
Trial completion date, Trial primary completion date: Cemiplimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery (clinicaltrials.gov) - Jul 26, 2024
P2, N=35, Recruiting, Sponsor: Thomas Jefferson University
Trial completion date: Jun 2024 --> Jul 2027 | Trial primary completion date: Jun 2024 --> Jul 2027
- | Libtayo (cemiplimab-rwlc) / Regeneron, fianlimab (REGN3767) / Regeneron
Enrollment change, Trial withdrawal: Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Adult Participants With Peri-operative Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC) (clinicaltrials.gov) - Jul 25, 2024
P2, N=0, Withdrawn, Sponsor: Regeneron Pharmaceuticals
Trial completion date: Jun 2024 --> Jul 2027 | Trial primary completion date: Jun 2024 --> Jul 2027 N=140 --> 0 | Not yet recruiting --> Withdrawn
- | Libtayo (cemiplimab-rwlc) / Regeneron
Biomarker, Trial completion date, Trial primary completion date: Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma (clinicaltrials.gov) - Jul 24, 2024
P1, N=30, Recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
N=140 --> 0 | Not yet recruiting --> Withdrawn Trial completion date: Jul 2026 --> Jun 2027 | Trial primary completion date: Jul 2024 --> Jun 2027
- Libtayo (cemiplimab-rwlc) / Regeneron
Prognostic Utility of Peripheral Myeloid Cells for Clinical Outcomes in Patients with NSCLC Treated with Cemiplimab (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1428;
P3
Conclusions : This analysis shows that peripheral blood cell count parameters, including putative immunosuppressive neutrophils and monocytes as well as protective lymphocytes and eosinophils, may predict outcomes with anti-PD-1 therapy in patients with advanced NSCLC. While the variables in the nomogram were statistically significant and enhanced the ability to discern difference over the baseline model, overall discrimination was moderate, indicating that more data are needed to better predict clinical outcomes in this setting.
- Libtayo (cemiplimab-rwlc) / Regeneron, fianlimab (REGN3767) / Regeneron
Phase 2 Peri-Operative Study of Fianlimab+Cemiplimab+Chemotherapy vs Cemiplimab+Chemotherapy in Resectable Early-Stage NSCLC (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1369;
P1, P2, P2
The key secondary endpoints are event-free survival by investigator assessment, major pathological response by BIPR, tumor response by investigator assessment, safety, pharmacokinetics, immunogenicity, and patient-reported outcomes. In addition, there are two Phase 2/3 studies (NCT05785767 and NCT05800015) exploring fianlimab + cemiplimab
- fianlimab (REGN3767) / Regeneron
Fianlimab-Based Combination Therapies in Patients with Advanced Non-Small Cell Lung Cancer: Trials in Progress Updates (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1223;
P1, P2, P2
Secondary endpoints for both studies include tolerability, safety, ORR per investigator assessment, disease control rate, time to tumor response, duration of response, progression-free survival, OS (Phase 2), patient-reported outcomes, pharmacokinetics, and immunogenicity. Both studies are currently open for enrollment, along with a third Phase 2 study in which fianlimab + cemiplimab + chemotherapy versus cemiplimab + chemotherapy will be evaluated as perioperative therapy in patients with stage II/III NSCLC (NCT06161441).
- Libtayo (cemiplimab-rwlc) / Regeneron, dalmitamig (REGN7075) / Regeneron
A Phase 1/2 Study of REGN7075 (EGFRA?-CD28) Combined with Cemiplimab (anti-PD-1) In NSCLC: Trial in Progress Update (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1219;
P1/2
As of February 23, 2024, 122 patients were enrolled in Part 1. The study is ongoing and open to enrollment.
- Libtayo (cemiplimab-rwlc) / Regeneron
Real-World Data (RWD) Of First-Line Cemiplimab Single Agent for Advanced PD-L1 High Expression, Non-Small Cell Lung Cancer (NSCLC) (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1169;
Conclusions : The RWD of cemiplimab demonstrated a favorable safety profile and efficacy outcomes consistent with pivotal trial and other RWD of anti PD-1/PD-L1 agents developed in this context. Extrathoracic disease and ECOG-PS emerged as significant factors associated with clinical outcomes in multivariate analysis.
- || Libtayo (cemiplimab-rwlc) / Regeneron
P2 data, Journal, HEOR, Metastases: Health-related quality of life in patients with metastatic basal cell carcinoma treated with cemiplimab: Analysis of a phase 2 trial. (Pubmed Central) - Jul 20, 2024
P2
Extrathoracic disease and ECOG-PS emerged as significant factors associated with clinical outcomes in multivariate analysis. The majority of patients treated with cemiplimab reported improvement or maintenance in GHS/QoL and functioning while maintaining a low symptom burden.
- THERAPEUTIC MODULATION OF GUT MICROBIOME TO TREAT IMMUNE-CHECKPOINT INHIBITORS-RELATED DIARRHEA AND COLITIS: EXPERIENCE OF A MICROBIOME CLINIC (Lehar 2) - Jul 18, 2024 - Abstract #UEGW2024UEGW_2375;
An approach based on gut microbiome modulation can be an effective strategy to treat ICI-related diarrhea and colitis, and may potentially reduce the need for steroids. Our preliminary findings should be confirmed by more consolidated and well designed studies.
- | Voyager-V1 / Vyriad, Libtayo (cemiplimab-rwlc) / Regeneron, Yervoy (ipilimumab) / BMS
New P1 trial: Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma (clinicaltrials.gov) - Jul 17, 2024
P1, N=20, Recruiting, Sponsor: Mayo Clinic
- || Libtayo (cemiplimab-rwlc) / Regeneron, Keytruda (pembrolizumab) / Merck (MSD), Tecentriq (atezolizumab) / Roche
Review, Journal, PD(L)-1 Biomarker, IO biomarker: Evolving Precision First-Line Systemic Treatment for Patients with Unresectable Non-Small Cell Lung Cancer. (Pubmed Central) - Jul 13, 2024
Lastly, for the remaining ~50% of patients who are fit and whose tumors have no or low PD-L1 expression (TPS of 0-49%) and no sensitizing EGFR/ALK aberrations, platinum-containing chemotherapy with the addition of a PD-1/L1 inhibitor alone or in combination of a cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitor improves PFS and OS compared to chemotherapy alone. The objectives of this review are to summarize the current data and perspectives on first-line systemic treatment in patients with unresectable NSCLC and propose a practical algorithm for implementing precision biomarker testing at diagnosis.
- || Libtayo (cemiplimab-rwlc) / Regeneron, Opdivo (nivolumab) / BMS, Cabometyx (cabozantinib tablet) / Exelixis, Ipsen
Biomarker, Review, Journal, PD(L)-1 Biomarker, IO biomarker: Exploring potential predictive biomarkers through historical perspectives on the evolution of systemic therapies into the emergence of neoadjuvant therapy for the treatment of hepatocellular carcinoma. (Pubmed Central) - Jul 12, 2024
Despite no widely recognized predictive biomarkers for HCC individualized treatment, we believe neoadjuvant trials hold the most promise in identifying and validating them. This is because they can collect multiple samples from resectable HCC patients across stages, especially with multi-omics, bridging preclinical and clinical gaps.
- ||| S95029 / Servier, S95018 / Servier
Enrollment open, IO biomarker: Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Jul 11, 2024
P1/2, N=176, Recruiting, Sponsor: Servier Bio-Innovation LLC
This is because they can collect multiple samples from resectable HCC patients across stages, especially with multi-omics, bridging preclinical and clinical gaps. Not yet recruiting --> Recruiting
- ||| E-602 / Palleon Pharma
Enrollment closed: Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01) (clinicaltrials.gov) - Jul 9, 2024
P1/2, N=273, Active, not recruiting, Sponsor: Palleon Pharmaceuticals, Inc.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Libtayo (cemiplimab-rwlc) / Regeneron
Journal, PD(L)-1 Biomarker, IO biomarker: Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer with PD-L1 (Pubmed Central) - Jul 6, 2024
P3
Recruiting --> Active, not recruiting In this subgroup analysis from EMPOWER-Lung 3 part 2, cemiplimab plus chemotherapy demonstrated clinical benefit over chemotherapy alone in patients with advanced squamous or non-squamous NSCLC with PD-L1
- | Libtayo (cemiplimab-rwlc) / Regeneron, Keytruda (pembrolizumab) / Merck (MSD)
Journal, Monotherapy, Real-world evidence, Real-world: Managing large cutaneous squamous cell carcinoma with programmed cell death protein 1 inhibitor monotherapy: Real-world experience at a single center. (Pubmed Central) - Jul 3, 2024
In this subgroup analysis from EMPOWER-Lung 3 part 2, cemiplimab plus chemotherapy demonstrated clinical benefit over chemotherapy alone in patients with advanced squamous or non-squamous NSCLC with PD-L1 No abstract available
- | Mekinist (trametinib) / Novartis, BeiGene, Libtayo (cemiplimab-rwlc) / Regeneron, Tafinlar (dabrafenib) / Novartis
Trial completion date, Trial primary completion date, IO biomarker: Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer (clinicaltrials.gov) - Jul 3, 2024
P2, N=15, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
No abstract available Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Jun 2024 --> Jun 2025
- ||| Journal, Adverse events, Checkpoint inhibition: Association of thrombocytopenia with immune checkpoint inhibitors: a large-scale pharmacovigilance analysis based on the data from FDA adverse event reporting system database. (Pubmed Central) - Jul 2, 2024
This study provides a comprehensive understanding of ICIs-induced ITP. Clinicians should pay attention to this potentially fatal adverse reaction.
- | Libtayo (cemiplimab-rwlc) / Regeneron
Journal, Checkpoint inhibition, Immunomodulating, Metastases: The Immunomodulatory Potential of Concurrent High-Dose Radiotherapy and Immune Checkpoint Inhibitor Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma: Initial Results. (Pubmed Central) - Jun 27, 2024
Despite the retrospective nature of this study and small sample size, our experience highlights the ability of concomitant radiotherapy and cemiplimab to promote an early objective response in patients with advanced CSCC. Moreover, in our population, the clinical benefits were also related to a longer progression-free survival, without any safety alert reported.
- | Libtayo (cemiplimab-rwlc) / Regeneron
Trial completion date, Trial primary completion date: Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jun 27, 2024
P2, N=34, Recruiting, Sponsor: City of Hope Medical Center
Moreover, in our population, the clinical benefits were also related to a longer progression-free survival, without any safety alert reported. Trial completion date: Jan 2028 --> Oct 2029 | Trial primary completion date: Jan 2028 --> Oct 2029
- ||| 27T51 / Regeneron
New P1 trial: A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers (clinicaltrials.gov) - Jun 21, 2024
P1, N=90, Not yet recruiting, Sponsor: Regeneron Pharmaceuticals
- | Krazati (adagrasib) / BMS, Libtayo (cemiplimab-rwlc) / Regeneron, Erbitux (cetuximab) / Eli Lilly
Enrollment change: A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations (clinicaltrials.gov) - Jun 18, 2024
P1/2, N=31, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Jan 2028 --> Oct 2029 | Trial primary completion date: Jan 2028 --> Oct 2029 N=16 --> 31
- |||| Libtayo (cemiplimab-rwlc) / Regeneron
Trial completion date, Trial primary completion date: EMPOWER-lung 1: Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Jun 17, 2024
P3, N=712, Active, not recruiting, Sponsor: Regeneron Pharmaceuticals
N=16 --> 31 Trial completion date: Apr 2024 --> Jun 2025 | Trial primary completion date: Apr 2024 --> Jun 2025
- |||| Libtayo (cemiplimab-rwlc) / Regeneron
New P2 trial: A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Jun 17, 2024
P2, N=120, Not yet recruiting, Sponsor: Regeneron Pharmaceuticals
- |||| olvimulogene nanivacirepvec (GL-ONC1) / Genelux
New P2 trial, Checkpoint inhibition: VIRO-25: Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer (clinicaltrials.gov) - Jun 17, 2024
P2, N=142, Not yet recruiting, Sponsor: Genelux Corporation
- || Review, Journal, HEOR, Checkpoint inhibition, Real-world evidence, Real-world: Immune checkpoint inhibitors-associated diabetes and ketoacidosis were found in FAERS: A Real-World Evidence Database Study. (Pubmed Central) - Jun 15, 2024
The study reveals the risk and characteristics of diabetes and ketoacidosis associated with ICIs, which may provide evidence for post-marketing evaluation. Careful consideration should be given to the possibility of an increased risk of diabetes and ketoacidosis after using ICIs, and careful monitoring for diabetes and ketoacidosis is recommended.
- | Libtayo (cemiplimab-rwlc) / Regeneron
Biomarker, Trial completion date, Trial primary completion date: BIOSELECT: BIOmarker-guided Study to Evaluate the Efficacy and Safety of cemipLimab for advancEd Cutaneous T-cell Lymphoma (clinicaltrials.gov) - Jun 14, 2024
P1/2, N=16, Not yet recruiting, Sponsor: AHS Cancer Control Alberta
Careful consideration should be given to the possibility of an increased risk of diabetes and ketoacidosis after using ICIs, and careful monitoring for diabetes and ketoacidosis is recommended. Trial completion date: Mar 2025 --> Mar 2026 | Trial primary completion date: Feb 2024 --> Feb 2025
- ||| BHV-1510 / Biohaven
Enrollment open, Monotherapy: A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors (clinicaltrials.gov) - Jun 13, 2024
P1/2, N=170, Recruiting, Sponsor: Pyramid Biosciences
Trial completion date: Mar 2025 --> Mar 2026 | Trial primary completion date: Feb 2024 --> Feb 2025 Not yet recruiting --> Recruiting
- || Libtayo (cemiplimab-rwlc) / Regeneron, fianlimab (REGN3767) / Regeneron
Phase classification: R3767-ONC-2011: Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma (clinicaltrials.gov) - Jun 10, 2024
P3, N=1590, Recruiting, Sponsor: Regeneron Pharmaceuticals
Not yet recruiting --> Recruiting Phase classification: P2/3 --> P3
- || Libtayo (cemiplimab-rwlc) / Regeneron
New P2 trial: NEO-SURG: Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node Involvement (clinicaltrials.gov) - Jun 10, 2024
P2, N=21, Not yet recruiting, Sponsor: Georgetown University
- || Libtayo (cemiplimab-rwlc) / Regeneron
Clinical data, Retrospective data, Journal, Metastases: Impact of cemiplimab treatment duration on clinical outcomes in advanced cutaneous squamous cell carcinoma. (Pubmed Central) - Jun 8, 2024
Phase classification: P2/3 --> P3 Among the 22 STS patients, 12 received cemiplimab for less than 12
- || Libtayo (cemiplimab-rwlc) / Regeneron, Erbitux (cetuximab) / Eli Lilly
New P2 trial: Cemiplimab and Cetuximab Prior Salvage Surgery in Patients With Recurrent Oral Cavity Squamous Cell Carcinoma (OCSCC). (clinicaltrials.gov) - Jun 6, 2024
P2, N=17, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- || Libtayo (cemiplimab-rwlc) / Regeneron
Biomarker, Clinical data, Journal: Clinical Outcomes and Prognostic Factors in Patients With Penile Carcinoma: A Sub-Analysis From Meet-URO 23 (I-RARE) Registry Study. (Pubmed Central) - Jun 6, 2024
In our registry study, PSCC is confirmed to be an aggressive disease. Poor ECOG PS, presence of lymph node metastases, and higher age at diagnosis appear to be associated with worse survival outcomes.
- | Libtayo (cemiplimab-rwlc) / Regeneron
Journal: Spontaneous regression of aggressive cutaneous squamous cell carcinoma. (Pubmed Central) - Jun 6, 2024
Poor ECOG PS, presence of lymph node metastases, and higher age at diagnosis appear to be associated with worse survival outcomes. No abstract available
- || ubamatamab (REGN4018) / Regeneron, Libtayo (cemiplimab-rwlc) / Regeneron
New P2 trial: Phase II Trial of Ubamatamab Alone or in Combination with Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies (clinicaltrials.gov) - Jun 5, 2024
P2, N=40, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- | Libtayo (cemiplimab-rwlc) / Regeneron
Biomarker, Journal, PD(L)-1 Biomarker, Metastases: Advanced cutaneous squamous cell carcinoma: Impact of age on the safety and efficacy of cemiplimab and the prognostic significance of blood biomarkers. (Pubmed Central) - Jun 5, 2024
Despite a higher incidence of primary progression and shorter OS in the oldest cohort, cemiplimab yielded robust objective responses regardless of age. Higher pre-treatment NLR was associated with shorter survival and the cut-point identified requires further study.
- | tuvusertib (M1774) / EMD Serono
Phase classification: Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322) (clinicaltrials.gov) - Jun 5, 2024
P1/2, N=180, Recruiting, Sponsor: EMD Serono Research & Development Institute, Inc.
Higher pre-treatment NLR was associated with shorter survival and the cut-point identified requires further study. Phase classification: P1b/2a --> P1/2
- ||| fianlimab/cemiplimab FDC (REGN3767/REGN2810 FDC) / Regeneron, Libtayo (cemiplimab-rwlc) / Regeneron, fianlimab (REGN3767) / Regeneron
Enrollment open, Trial initiation date: A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery (clinicaltrials.gov) - Jun 4, 2024
P2, N=180, Recruiting, Sponsor: Regeneron Pharmaceuticals
Phase classification: P1b/2a --> P1/2 Not yet recruiting --> Recruiting | Initiation date: Mar 2024 --> Jun 2024
- ||| IO-108 - Immune / Onc Therap
Trial completion, Enrollment change, Monotherapy: IO-108-CL-001: First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jun 3, 2024
P1, N=91, Completed, Sponsor: Immune-Onc Therapeutics
Not yet recruiting --> Recruiting | Initiation date: Mar 2024 --> Jun 2024 Active, not recruiting --> Completed | N=309 --> 91
- | Lynozyfic (linvoseltamab) / Regeneron, Sanofi
Trial completion date: LINKER-MM2: A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments (clinicaltrials.gov) - May 30, 2024
P1, N=317, Recruiting, Sponsor: Regeneron Pharmaceuticals
Active, not recruiting --> Completed | N=309 --> 91 Trial completion date: Aug 2032 --> Jan 2033
- | Libtayo (cemiplimab-rwlc) / Regeneron
Journal, PD(L)-1 Biomarker, Metastases: Good clinical response to cemiplimab in a young patient with locally advanced cutaneous squamous cell carcinoma on preexisting recessive dystrophic epidermolysis bullosa. (Pubmed Central) - May 29, 2024
During follow-up, the patient had a notable clinical response with no auto-immune adverse reactions. This shows that cemiplimab has a good safety profile for cSCC in patients with RDEB and is a valuable therapy option.
- || Libtayo (cemiplimab-rwlc) / Regeneron, fianlimab (REGN3767) / Regeneron
Enrollment open: Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer (clinicaltrials.gov) - May 28, 2024
P2, N=22, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
This shows that cemiplimab has a good safety profile for cSCC in patients with RDEB and is a valuable therapy option. Not yet recruiting --> Recruiting
- || Libtayo (cemiplimab-rwlc) / Regeneron, Keytruda (pembrolizumab) / Merck (MSD)
Review, Journal: Guidelines for the diagnosis and treatment of cutaneous squamous cell carcinoma: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology. (Pubmed Central) - May 26, 2024
These guidelines, developed by the Italian Association of Medical Oncologists (AIOM) using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) approach, aim to guide clinicians in diagnosing, treating, and monitoring patients with CSCC, covering key aspects from primitive tumors to advanced stages, selected by a panel of experts selected by AIOM and other national scientific societies. The incorporation of these guidelines into clinical practice is expected to enhance patient care and address the evolving landscape of CSCC management.
- | Trial completion date, Trial primary completion date, Checkpoint inhibition, IO biomarker: Exercise to Boost Response to Checkpoint Blockade Immunotherapy (clinicaltrials.gov) - May 22, 2024
P1, N=32, Recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
The incorporation of these guidelines into clinical practice is expected to enhance patient care and address the evolving landscape of CSCC management. Trial completion date: May 2024 --> Sep 2024 | Trial primary completion date: May 2024 --> Sep 2024
- || Libtayo (cemiplimab-rwlc) / Regeneron
Enrollment open, Trial initiation date, Tumor mutational burden: The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer (clinicaltrials.gov) - May 21, 2024
P2, N=50, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: May 2024 --> Sep 2024 | Trial primary completion date: May 2024 --> Sep 2024 Not yet recruiting --> Recruiting | Initiation date: Jan 2025 --> May 2024
- | Libtayo (cemiplimab-rwlc) / Regeneron, Erbitux (cetuximab) / Eli Lilly
New P2 trial: NEOPECS: Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma (clinicaltrials.gov) - May 20, 2024
P2, N=27, Not yet recruiting, Sponsor: Melanoma and Skin Cancer Trials Limited
- || Libtayo (cemiplimab-rwlc) / Regeneron, Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS
Review, Journal, Metastases: Metastatic patterns and treatment options for head and neck cutaneous squamous cell carcinoma (Review). (Pubmed Central) - May 17, 2024
Notably, there is an urgent need to identify patients who may benefit from local or systemic cancer treatments. The treatment of lymph node metastasis presents a therapeutic challenge and requires comprehensive management.
- ||| Clinical, Retrospective data, Journal, Adverse events, Checkpoint inhibition: Adverse events associated with immune checkpoint inhibitors in non-small cell lung cancer: a safety analysis of clinical trials and FDA pharmacovigilance system. (Pubmed Central) - May 15, 2024
As far as any or grades 3-5 irAEs are concerned, atezolizumab plus bevacizumab plus chemotherapy is considered the most safety option...These findings revealed that ICIs differed in their safety profile. ICI treatment strategies can be improved and preventive methods can be developed for NSCLC patients based on our results.
- ||||| Libtayo (cemiplimab-rwlc) / Regeneron, fianlimab (REGN3767) / Regeneron
Phase classification, Enrollment change, Trial completion date, Trial initiation date, Trial primary completion date: R3767-ONC-2208: A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma (clinicaltrials.gov) - May 15, 2024
P2/3, N=520, Not yet recruiting, Sponsor: Regeneron Pharmaceuticals
ICI treatment strategies can be improved and preventive methods can be developed for NSCLC patients based on our results. Phase classification: P2 --> P2/3 | N=360 --> 520 | Trial completion date: Dec 2030 --> Jun 2033 | Initiation date: Feb 2024 --> Jul 2024 | Trial primary completion date: Dec 2030 --> Sep 2028